The Curie Institute, a flagship of French research, recently revealed a feat: a simple blood test could allow anticipating a relapse of breast cancer. A discovery that currently encourages the Congress of Asco (American Society of Clinical Oncology) that brings together the International Scientific and Medical Community in Oncology in Chicago from May 30 to June 6.
Ludivine Ernultt, patient at the Institut Curie, is one of those women who participated in this clinical trial. Mother of two children, could try this blood test two years ago to detect DNA fraud, allowing to detect a possible recurrence of breast cancer.
“I participated in this study that quickly highlighted a very early recurrence, which allowed my oncologist to establish a protocol of attention immediately,” he entrusts BFMTV.
Almost 60,000 new cases each year
Express detection that allowed him to begin chemotherapy only 10 days after taking blood, unlike a conventional surveillance route where detection takes place in several months. “
As part of breast cancer after treatment, radiological exams remain insufficient to detect early recurrences. This blood test seems to be a revolutionary scientific advance for the future of thousands of affected women.
“The objective is to detect previously treated cancer relapses and ideally begin local treatments to prevent the dissemination and generalization of cancer, explains the oncologist of the Institut Curie François-Clément Bidard.
A blood analysis that also allows you to “start treatments before,” adds the doctor.
In France, it is the most common cancer in women, with almost 60,000 new cases diagnosed every year in France.
Source: BFM TV
